Activation of PI3K pathway via mutations in PIK3CA has been reported in NSCLC patients with HER2 TKIs resistance, and combined therapy of mTOR inhibitor showed therapeutic response.270. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.